AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company that became a publicly traded entity following its business combination with Priveterra Acquisition Corp, a blank-check vehicle sponsored by Priveterra Sponsor LLC that completed its initial public offering in 2021. Operating in the therapeutics sector, AEON focuses on developing botulinum toxin complex candidates targeting gastrointestinal, urological, and other medical indications. The company filed its Form 10-Q on May 12, 2022, under accession number 0001104659-22-059538, reflecting its status as a reporting company in the period shortly after the de-SPAC transaction closed. Sign up on SpacDesk for full filing histories, sponsor profiles, and deal-level analytics on AEON and the broader SPAC universe.